Connect your AI

Neuronetics STIM Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

LBR

LB Pharmaceuticals Inc Common StockLBRX

$1.17M—

Other financials

Income statement

Revenue$34.5M+7.8%

Gross profit$16.2M+2.6%

Operating income-$9.0M+18.3%

Net income-$10.8M+14.9%

EPS (diluted)-$0.16+23.8%

Balance sheet

Cash & equivalents$13.2M-34.7%

Total debt$85.4M+3.5%

Total equity$13.3M-62.6%

Total assets$125.4M-11.7%

Cash flow

Operating cash flow-$9.4M+44.6%

CapEx$197.0K-10.0%

Free cash flow-$9.6M+44.1%

Valuation

Market cap$90.46M-56.2%

Enterprise value$162.64M-42.0%

P/S0.6×-1.3×

Profitability

Gross margin48%-15.6pp

Operating margin-19.4%-6.9pp

Net margin-24.5%-8.7pp

FCF margin-9.4%-4.1pp

Returns & leverage

Return on equity-152.4%-1.4pp

Debt / equity6.4×+4.1×

Current ratio1.7×-0.8×

Where this comes from

Reported directly by Neuronetics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Neuronetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neuronetics's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Neuronetics's payments of stock issuance costs?: Neuronetics (STIM) reported payments of stock issuance costs of $1.73M in Q1 2025.